biotech industry
Coverage of biotech industry in the Nexus archive.
- STAT+: At BIO 2026, industry wrestled with Washington politics, and making AI work better
At the 2026 BIO conference in San Diego, biotech and startup executives discussed challenges posed by China's growing influence in drug development, strategies to strengthen the U.S. biotech industry, and the role of artificial intelligence in gaining competitive advantages. Key topics included navigating Washington politics, addressing pricing policies, and accelerating AI adoption.
- China rapidly catching up with US in biotech
China is rapidly catching up with the US in biotech capabilities, leading in manufacturing and clinical development while the US maintains an edge in talent and market translation. The US has responded with measures like restricting federal dealings with foreign biotech firms and accelerating drug research to restore leadership in clinical trials.
- China’s biotech industry sees global expansion as unstoppable, despite US pressure
China’s biotech firms are advancing global expansion despite U.S. investment restrictions and national security measures. Industry insiders describe the trend as 'irreversible,' with U.S. regulatory and non-tariff barriers cited as challenges for Chinese companies entering the American market.